HARROW, INC.
Close on Oct 19, 2026
- Market cap
- $1.03B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $70.70M | $-0.46 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | $44.20M | $-0.74 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 2, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | After market close | $71.60M | $0.03 | $0.33 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 10, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | full-year 2026 | $80.00M to $100.00M | New |
| revenue | full-year 2026 | $350.00M to $365.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Harrow filed with the SEC
Harrow Closes Acquisition of TYRVAYA®
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Acquires Global Rights to TYRVAYA ® ,
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
first quarter of 2026 saw unprecedented market demand for VEVYE ® and an unavoidable modeling challenge related to our
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030
Other events · EX-99.1 to Form 8-K
Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Harrow reported record fourth quarter revenues of $89.1 million, a 33% increase over the prior year’s fourth quarter revenues of
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million,
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Announces Closing of Acquisition of Melt Pharmaceuticals
Acquisition or disposition completed · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
the third quarter of 2025, Harrow continued to emerge as a leader in providing ophthalmic disease management solutions in North America.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Mullery Appointed Chief Executive Officer of ImprimisRx
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
Other events · EX-99.1 to Form 8-K
Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Announces Second-Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
we report on the second quarter of 2025, Harrow continues to solidify its position as a leading provider of ophthalmic disease management
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Enters into Commercialization Agreement with Samsung Bioepis
Other events · EX-99 to Form 8-K
Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
Other events · EX-99 to Form 8-K
Announces First-Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Today, we reported first-quarter 2025
Results of operations · EX-99.2 to Form 8-K
Announces Fourth-Quarter and Year-End 2024 Audited Financial Results
Results of operations · EX-99.1 to Form 8-K
had a tremendous close to a monumental year – and today, I am pleased to report another period of record financial performance
Results of operations · EX-99.2 to Form 8-K
Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance
Results of operations · EX-99.1 to Form 8-K
Announces Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
began writing this Stockholder Letter from Madison, Wisconsin, at the home of an old friend who happens to be a Harrow founding stockholder.
Results of operations · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
last Letter to Stockholders outlined three of Harrow’s key operational initiatives from our Five-Year Strategic Plan (see page
Results of operations · EX-99.2 to Form 8-K